Iambic Therapeutics, a clinical-stage life sciences and technology company, has priced its initial public offering of 9,375,000 shares of common stock at US$16.00 per share. All shares are being offered by Iambic, and gross proceeds are expected to reach US$150 million before underwriting discounts, commissions, and other offering expenses. The company's common stock is expected to begin trading on the Nasdaq Global Select Market on October 15, 2026, under the ticker symbol IAM.
Company Mission and Platform
Iambic's mission is to make better technology for better medicines by utilizing molecular superintelligence, which combines proprietary AI with automated, scalable chemistry and biology experimentation. The company's platform is designed to address the totality of drug discovery and development across multiple stages. This integrated approach aims to improve the speed, precision, and success rates of the company's drug discovery and clinical development programs.
Pipeline Validation
Iambic highlights IAM1363, a novel drug candidate that advanced to the clinic in approximately two years, as evidence of its platform's utility and efficiency. The candidate is supported by a diverse preclinical pipeline that spans multiple therapeutic programs and indications. This rapid progression reflects the company's focus on accelerating drug discovery timelines through its combined AI and automated experimental approach.
Key AI Technologies
The company's leading AI technologies include Enchant and NeuralPLexer, both designed for multimodal endpoint prediction. These tools are intended to improve speed, precision, and success rates across drug discovery and clinical development. Iambic describes this technology stack as an engine designed to power the future of medicine by enabling more accurate predictions and improved patient outcomes.
Offering Details and Underwriters
All shares in the initial public offering are being sold by Iambic, with no selling stockholders participating in the transaction. The underwriters have been granted a 30-day option to purchase up to 1,406,250 additional shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on October 16, 2026, subject to customary closing conditions, with J.P. Morgan, Jefferies, BofA Securities, and Citigroup acting as joint book-running managers.
Regulatory Filing and Prospectus
A registration statement relating to the offering has been filed with the Securities and Exchange Commission and became effective on October 14, 2026. The offering is being made only by means of a prospectus, and a copy of the final prospectus will be available at the SEC website once filed. Investors may also obtain copies from J.P. Morgan, Jefferies, BofA Securities, or Citigroup when the final prospectus is available.
Forward-Looking Statements
The announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties, assumptions, and other factors that could cause actual results to differ materially from those anticipated. Iambic undertakes no obligation to update any forward-looking statements except as required by law.
The initial public offering represents a significant capital milestone for Iambic, with expected gross proceeds of US$150 million before underwriting discounts and commissions. These funds are expected to support the company's continued investment in its AI-driven drug discovery platform and clinical development programs. As Iambic begins trading on Nasdaq, its public debut highlights growing investor interest in technology-enabled life sciences companies.